Inbec需要注意什么事项呢？

In January 2018, ViiV Healthcare, a joint venture company under the British multinational pharmaceutical company GlaxoSmithKline (GSK), officially launched the innovative AIDS treatment drug Suimika () in the Chinese market.

Inbec is the only three-in-one compound drug containing dolutegravir (DTG), which integrates treatment drugs for different stages of viral infection in the same tablet. Patients only need to take one drug to achieve the effect of combined medication. The drug has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection.

Common adverse reactions of Inbec include nausea (12%), insomnia (7%), dizziness (6%) and headache (6%). Patients with abacavir hypersensitivity often experience nausea, vomiting, diarrhea, fever, drowsiness, rash and other symptoms when using this product. If patients experience these symptoms, they should be carefully evaluated for the presence of such a hypersensitivity reaction. Very rarely, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis may occur, and abacavir hypersensitivity cannot be excluded. In such cases, abacavir-containing medicinal products should be permanently discontinued.

Although viral suppression with antiretroviral therapy has been shown to significantly reduce the risk of sexual transmission, residual risks cannot be excluded. Precautions should be taken to prevent transmission in accordance with national guidance.

Suimeikai () is suitable for adults and adolescents over 12 years old and weighing at least 40kg. Adults or adolescents who weigh less than 40kg should not be given Inbec because Inbec is a fixed-dose tablet and the dose cannot be reduced. It is best to take Inbec at regular times every day. If the patient misses a dose of Inbec and there are more than 4 hours before the next dose, Inbec should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.